News
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership...
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage...
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development...
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K antagonist will present at the 2025 BIO CEO &...
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on...
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic anticoagulant therapy for warfarin-dependent patients...
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan...
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla., Nov. 19, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a...
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit PONTE VEDRA, Fla., Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage...
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
PONTE VEDRA, Fla., Nov. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and superior...